Los Angeles Capital Management & Equity Research Inc. purchased a new stake in Sarepta Therapeutics Inc (NASDAQ:SRPT) in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 2,180 shares of the biotechnology company’s stock, valued at approximately $260,000.
Other institutional investors also recently added to or reduced their stakes in the company. Northern Trust Corp boosted its holdings in shares of Sarepta Therapeutics by 6.5% in the fourth quarter. Northern Trust Corp now owns 318,287 shares of the biotechnology company’s stock valued at $34,734,000 after buying an additional 19,473 shares during the period. Meeder Asset Management Inc. boosted its holdings in Sarepta Therapeutics by 1,621.5% during the fourth quarter. Meeder Asset Management Inc. now owns 2,565 shares of the biotechnology company’s stock worth $281,000 after purchasing an additional 2,416 shares during the last quarter. Columbus Circle Investors boosted its holdings in Sarepta Therapeutics by 57.7% during the first quarter. Columbus Circle Investors now owns 392,243 shares of the biotechnology company’s stock worth $46,751,000 after purchasing an additional 143,552 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in Sarepta Therapeutics by 1,939.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 7,282 shares of the biotechnology company’s stock worth $795,000 after purchasing an additional 6,925 shares during the last quarter. Finally, Piedmont Investment Advisors Inc. boosted its holdings in Sarepta Therapeutics by 6.2% during the fourth quarter. Piedmont Investment Advisors Inc. now owns 4,821 shares of the biotechnology company’s stock worth $526,000 after purchasing an additional 280 shares during the last quarter. Institutional investors own 93.48% of the company’s stock.
NASDAQ SRPT opened at $115.85 on Wednesday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 7.49 and a current ratio of 8.21. Sarepta Therapeutics Inc has a 1 year low of $86.55 and a 1 year high of $176.50. The firm has a market cap of $8.62 billion, a price-to-earnings ratio of -21.22 and a beta of 1.98.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.05) by $0.98. Sarepta Therapeutics had a negative net margin of 124.66% and a negative return on equity of 42.67%. The firm had revenue of $87.01 million for the quarter, compared to analyst estimates of $86.92 million. Equities research analysts anticipate that Sarepta Therapeutics Inc will post -4.71 EPS for the current year.
Several research analysts recently commented on SRPT shares. Royal Bank of Canada restated an “outperform” rating and set a $164.00 target price on shares of Sarepta Therapeutics in a report on Thursday, January 17th. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, January 23rd. Piper Jaffray Companies increased their target price on shares of Sarepta Therapeutics from $168.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, January 30th. BidaskClub upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Finally, BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, February 5th. One research analyst has rated the stock with a hold rating, twenty-seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $193.00.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: Fiduciary
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.